O'Brien Paul E, Dixon John B, Brown Wendy, Schachter Linda M, Chapman Leon, Burn Anthony J, Dixon Maureen E, Scheinkestel Carlos, Halket Christine, Sutherland Lisa J, Korin Anna, Baquie Peter
Monash Department of Surgery, Alfred Hospital, Melbourne 3181, Australia.
Obes Surg. 2002 Oct;12(5):652-60. doi: 10.1381/096089202321019639.
Obesity is now one of our major public health problems. Effective and acceptable treatment options are needed. The Lap-Band system is placed laparoscopically and allows adjustment of the level of gastric restriction.
A prospective study of 709 severely obese patients was conducted over a 6-year period at a university-based multidisciplinary referral center. After extensive preoperative evaluation, patients with a body mass index > 35 were treated by Lap-Band placement. Close follow-up with progressive adjustment of gastric restriction continued permanently. Medical co-morbidities were monitored as part of comprehensive prospective data collection.
There have been no deaths perioperatively or during follow-up. Significant perioperative adverse events occurred in 1.2% only. Reoperation has been needed for prolapse (slippage) in 12.5%, erosion of the band into the stomach in 2.8% and for tubing breaks in 3.6%. A steady progression of weight loss has occurred through the duration of the study with 52 +/- 19% EWL at 24 months (n = 333), 53 +/- 22% EWL at 36 months (n = 264), 52 +/- 24% EWL at 48 months (n = 108), 54 +/- 24% EWL at 60 months (n = 30), and 57 +/- 15% EWL at 72 months (n = 10). Major improvements have occurred in diabetes, asthma, gastroesophageal reflux, dyslipidemia, sleep apnea and depression. Quality of life as measured by Rand SF-36 shows highly significant improvement.
Placement of the Lap-Band system provides safe and effective control of severe obesity. The effect on weight loss is durable and is associated with major improvement in health and quality of life. It has the potential to provide a broadly acceptable option for this common and serious disease.
肥胖现已成为我们主要的公共卫生问题之一。需要有效且可接受的治疗方案。胃束带系统通过腹腔镜置入,可调节胃限制水平。
在一所大学的多学科转诊中心,对709例重度肥胖患者进行了为期6年的前瞻性研究。经过广泛的术前评估,体重指数>35的患者接受胃束带置入治疗。持续进行密切随访,并逐步调整胃限制。作为全面前瞻性数据收集的一部分,对合并症进行监测。
围手术期及随访期间均无死亡病例。围手术期严重不良事件仅发生在1.2%的患者中。因胃束带脱垂(滑脱)需再次手术的患者占12.5%,束带侵蚀胃壁的患者占2.8%,导管断裂的患者占3.6%。在研究期间体重持续稳步下降,24个月时的超重减少率(EWL)为52±19%(n = 333),36个月时为53±22%(n = 264),48个月时为52±24%(n = 108),60个月时为54±24%(n = 30),72个月时为57±15%(n = 10)。糖尿病、哮喘、胃食管反流、血脂异常、睡眠呼吸暂停和抑郁症均有显著改善。通过兰德36项健康调查简表(Rand SF-36)测量的生活质量有高度显著改善。
胃束带系统置入可安全有效地控制重度肥胖。其减肥效果持久,并与健康状况和生活质量的显著改善相关。它有可能为这种常见且严重的疾病提供一种广泛可接受的选择。